FDA Approves First Drug for Eosinophilic Esophagitis

Dupilumab (Dupixent) is approved to treat eosinophilic esophagitis in adults and children aged 12 years and older weighing at least 40 kg.
FDA Approvals
Dupilumab (Dupixent) is approved to treat eosinophilic esophagitis in adults and children aged 12 years and older weighing at least 40 kg.
FDA Approvals